Alert

Repeal of Medical Device Excise Tax Alleviates Uncertainty for Device Companies

Rich Croghan, Principal, Life Sciences Practice

January 13, 2020
LinkedIn Share Button Twitter Share Button Other Share Button Other Share Button

In December 2019, President Trump signed into law the repeal of the Medical Device Excise Tax, which was included in the omnibus spending bills for fiscal year 2020.

Long sought by the industry, the repeal was initially passed by the US House of Representatives and the US Senate in December 2019. This change helps alleviate uncertainty related to investment and innovation in medical device companies.

Background

The medical device tax was enacted as part of the Patient Protection and Affordable Care Act. It was originally effective in January 2013, but the US Congress passed temporary measures suspending the tax for 2016 and 2017, and then again for 2018 and 2019.

We’re Here to Help

To learn more about the Medical Device Excise Tax or what the repeal means for you or your company, contact your Moss Adams professional.

Ask a Question

The material appearing in this communication is for informational purposes only and should not be construed as advice of any kind, including legal, accounting, tax, or investment advice. This information is not intended to create, and receipt does not constitute, a legal relationship, including, but not limited to, an accountant-client relationship. Although these materials have been prepared by professionals, the user should not substitute these materials for professional services, and should seek advice from an independent advisor before acting on any information presented. Changes in tax laws or other factors could affect the information provided in this communication.

Related Topics

Article
How Pharmaceutical Companies Can Claim the Orphan Drug Tax Credit
Article
View More

Contact Us with Questions

Baker Tilly US, LLP, Baker Tilly Advisory Group, LP and Moss Adams LLP and their affiliated entities operate under an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations and professional standards. Baker Tilly Advisory Group, LP and its subsidiaries, and Baker Tilly US, LLP and its affiliated entities, trading as Baker Tilly, are members of the global network of Baker Tilly International Ltd., the members of which are separate and independent legal entities. Baker Tilly US, LLP and Moss Adams LLP are licensed CPA firms that provide assurance services to their clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and consulting services to their clients and are not licensed CPA firms. ISO certification services offered through Moss Adams Certifications LLC. Investment advisory offered through either Moss Adams Wealth Advisors LLC or Baker Tilly Wealth Management, LLC.